Drugs / Parvovirus H-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02653313 | Dec 2015 → May 2018 | pancreatic ductal adenocarcinoma | Oryx GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Parvovirus H-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02653313 ↗ |
| Known as | H-1PV | “Parvovirus H-1 (H-1PV)” NCT02653313 ↗ |
| Known as | ParvOryx | “Parvovirus H-1 (ParvOryx)” NCT02653313 ↗ |
| Route | Intravenous | “intravenous infusions” NCT02653313 ↗ |